← board
BGMSP
distress 7/10 · high distress / dilution risk$3.500%today-51% from 52w high
Revenue
pre-revenue
Liquidity
$8M
Runway
1.1 yrs
Shares 1y
+147%
Price & events
+18.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+150.0%
1W
+323.2%
1M
+250.0%
3M
+18.9%
6M
-13.7%
1Y
-51.4%
2Y
-53.4%
5Y
-23.5%
All
Overview
- Market Cap
- $19.32M
- Volume
- 0
- 52 Week Range
- $0.30 – $7.21
- Total Shares
- 5.52M
- Float Shares
- 3.46M
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 1.39%
- Beta
- -0.37
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- 2025-10-01partnershipplogosertib · Sale of all patent rights related to Plogosertib to Tethra BiosciencesSEC 8-K
- 2025-09-12partnershipAcquisition of Fitters Sdn. Bhd., a fire safety companySEC 8-K
- 2025-05-06partnershipShare exchange agreement to acquire Fitters Sdn. Bhd., making it a wholly-owned subsidiary.SEC 8-K
- 2025-01-24withdrawalfadraciclib · Liquidation of UK subsidiary Cyclacel Limited; cessation of fadraciclib programSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.